Abstract
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of human malignancies and its expression is associated with tumor aggressiveness and treatment resistance. The monoclonal antibody cetuximab (IMC-C225) blocks the ligand binding domain of EGFR, preventing downstream signaling and is increasingly used in a clinical setting. To assess in vivo binding of cetuximab to EGFR, we developed a new imaging probe using cetuximab labeled with the PET isotope Zirconium-89.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
